Genetron Health Gets CE Mark for Multigene Mutation Detection Kit, Onco PanScan

Genetron Holdings has obtained a CE mark for its large-panel product, Onco PanScan (Mutation Detection Kit for Human Multigenes).

Genetron Holdings is a Beijing, China-based precision oncology company that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development.

Onco PanScan is a genomic profiling test based on hybridization capture and next-generation sequencing technology. By combining coverage of different gene mutation regions and genetic variants observed in thousands of cases from different tumor types, the detection kit covers more than 800 genes that are recommended under international treatment guidelines, the company says.